Cardiff Oncology, Inc.

NASDAQ:CRDF

Biotechnology

Healthcare
$0.84 +2.12%

+$0.03 today

Market cap
$65.27M
Beta
1.38
P/E (TTM)
-1.8
EPS (TTM)
-$0.65
52W Low $1.16High $4.56

Volume 0.86M

Average 1.05M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

-$37.92M

FY 2025 · Annual

Investing Cash Flow

$1.34M

FY 2025 · Annual

-90.2% YoY

Financing Cash Flow

$2.58M

FY 2025 · Annual

-95.2% YoY

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(28.29M)(38.7M)(41.44M)(45.43M)(45.85M)
Depreciation & Amortization451K236K398K404K904K
Deferred Income Tax1.32M0000
Stock-Based Compensation3.23M4.26M4.51M4.76M5.69M
Change in Working Capital(1.79M)(380K)6.57M3.17M2.18M
Accounts Receivables(215K)(236K)483K(484K)591K
Inventory00000
Accounts Payables719K1.35M2.83M2.99M2.2M
Other Working Capital(2.29M)(1.49M)3.25M671K(614K)
Other Non-Cash Items2.03M772K(921K)(598K)(848K)
Operating Cash Flow(23.04M)(33.82M)(30.89M)(37.69M)(37.92M)
Capital Expenditures(205K)(892K)(582K)(80K)(44K)
Acquisitions (Net)205K(114K)000
Purchases of Investments(174.39M)(91.23M)(70.08M)(23.56M)(71.12M)
Sales of Investments43.14M130.27M106.86M37.37M73.25M
Other Investing Activities(205K)114K00(744K)
Investing Cash Flow(131.45M)38.15M36.2M13.73M1.34M
Debt Repayment00000
Common Stock Issued34.19M75K053.41M2.58M
Common Stock Repurchased00000
Dividends Paid(24K)(414K)000
Other Financing Activities1.29M414K0373K0
Financing Cash Flow35.45M75K053.78M2.58M
Effect of Forex Changes00000
Net Change in Cash(119.04M)4.4M5.31M29.82M(34M)
Free Cash Flow(23.25M)(34.71M)(31.47M)(37.77M)(37.97M)

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income-$45.9M
+ D&A$904.0K
+ Stock-Based Comp$5.7M
+ Deferred Tax$0
+ Working Capital$2.2M
- Other Non-Cash-$848.0K
= Operating Cash Flow-$37.9M
- Capex-$44.0K
= Free Cash Flow-$38.0M

Analysis

FY2025 free cash flow is -$38.0M. FCF conversion is 82.8% of net income. Operating cash flow was -$37.9M, with capex of -$44.0K. The largest bridge item is Stock-Based Comp at $5.7M.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
8-KCurrent reportNov 12, 2026
10-QQuarterly reportNov 12, 2026
3Initial statement of beneficial ownershipOct 27, 2026
8-KCurrent reportOct 27, 2026
8-KCurrent reportOct 22, 2026

Does CRDF generate free cash flow?

Cardiff Oncology, Inc. (CRDF) generated -$37.97M of free cash flow in fiscal 2025.

How much operating cash flow does CRDF produce?

Operating cash flow was -$37.92M, before capital expenditures of $44,000.00.